Our results demonstrate that following intravenous injection of EF5, binding and detection using a monoclonal antibody in 9L gliomas is specific and oxygen dependent.
In previous studies, we have accomplished early OA detection using a fluorescent selectively binding monoclonal antibody (Mab) which binds exposed CII in the articular cartilage.
Specific antibody binding was detected using a chemiluminescence detection system (Pierce, Rockford, IL, United States), according to the manufacturer's recommendations.
Antibody binding was detected using an enhanced chemiluminescence detection system (Cell Signaling Technology, Milano, Italy).
Secondary-antibody binding was detected using an enhanced chemiluminescence detection kit (Thermo Fisher Scientific, USA) according to the manufacturer's instructions.
Secondary-antibody binding was detected using an enhanced chemiluminescence detection kit (Amersham, Piscataway, NJ, USA) according to the manufacturer′s instructions.
Western blotting was carried out used standard techniques and antibody binding was detected using an enhanced chemiluminescence (ECL) detection kit (Amersham, Buckinghamshire, UK) following the manufacturer's protocol.
Antibody binding was detected using an enhanced chemiluminescence HRP substrate detection kit (Millipore, Watford, UK).
Specific bindings were detected using an "ECL plus" Western blot detection system (Amersham Biosciences).
After washing the plates and blocking of unspecific binding sites, c-jun was detected using an ELISA detection reaction.
